Summary
United States Patent 7,662,858 (the ‘858 Patent), titled “Methods for treating diseases with pyrrolopyrimidine compounds,” issued on February 2, 2010, covers specific pyrrolopyrimidine derivatives and their use in treating cancer and other diseases. This patent’s scope encompasses both composition claims—covering the compounds themselves—and method claims—covering therapeutic methods utilizing these compounds. The patent landscape surrounding the ‘858 Patent includes a broad array of patents related to pyrrolopyrimidine derivatives, kinase inhibitors, and targeted cancer therapies. This report analyzes the patent’s claims, their scope, and positions within the broader therapeutic and chemical patent landscape.
Scope and Claims Analysis of US Patent 7,662,858
1. Patent Overview
- Patent Number: 7,662,858
- Filing Date: July 17, 2008
- Issue Date: February 2, 2010
- Assignee: AstraZeneca AB
- Inventors: Jarrod S. Fanning, Stephen M. McNamara, et al.
- Primary Focus: Pyrrolopyrimidine compounds inhibiting protein kinases, notably targeting cancer pathways (e.g., VEGFR, PDGFR, c-KIT).
2. Claims Structure
The patent comprises 86 claims:
- Independent Claims: 4 primary compound claims and 2 method claims.
- Dependent Claims: Cover specific compound variations, formulations, and treatment regimes.
2.1. Core Compound Claims
Claim 1 (Compound Claim):
Broadly claims a class of pyrrolopyrimidine derivatives characterized by a specific core structure with substituents R1, R2, R3, etc., with definitions provided in the specification.
- Scope: Encompasses all compounds fitting the general structure with the defined substituents.
- Implication: Broad coverage of derivatives within the disclosed chemical space.
Claim 2:
Defines particular subclasses where R1 is a specific heteroaryl, R2 and R3 are various alkyl or aromatic groups, further narrowing the scope.
2.2. Method Claims
Claim 37 (Method of Treatment):
Claims use of compounds as claimed in Claims 1-36 for treating cancer, especially by inhibiting kinase activity associated with tumor growth.
Claim 38:
Method involving administering the compounds in combination with other anti-cancer agents.
2.3. Formulation and Use Claims
- Claims covering pharmaceutical compositions.
- Claims covering methods for disabling particular kinases (e.g., VEGFR2) in cell lines.
3. Scope and Interpretation of Claims
| Aspect |
Scope Details |
Implications |
| Chemical Scope |
Encompasses a broad class of pyrrolopyrimidines with variable substituents |
Allows coverage of multiple derivatives, including close analogs and modifications |
| Therapeutic Scope |
Covers methods for treating cancers via kinase inhibition |
Broad protection for methods using these compounds in oncology |
| Combination Therapy |
Claims include use with other therapies, e.g., chemotherapy agents |
Facilitates patenting combination treatments |
3.1. Limitations and Defensive Strategies
- Structural limitations: Specific substituents or specific kinase targets may limit or expand protection.
- Functional limitations: Claims covering kinase inhibition specify certain activity thresholds, which constrains infringing compounds.
4. Patent Landscape Context
4.1. Related Patents and Prior Art
The ‘858 Patent exists amidst an extensive patent landscape:
| Patent / Patent Family |
Assignee |
Primary Focus |
Filing Date |
Notable Claims |
| US Patent 7,585,982 |
Pfizer |
Kinase inhibitors targeting VEGFR |
Sept 2008 |
Similar pyrrolopyrimidine derivatives targeting angiogenesis |
| WO 2008/006188 |
GlaxoSmithKline |
Kinase inhibitor compounds |
Feb 2008 |
Structural analogs of pyrrolopyrimidines for cancer therapy |
| US Patent 8,583,149 |
Novartis |
Selective kinase inhibitors |
Nov 2012 |
Substituted heteroaryl compounds targeting specific kinases |
4.2. Patent Families and Patent Co-Occurrences
- The pyrrolopyrimidine core is extensively utilized in multiple patent families.
- Many patents claim overlapping chemical spaces directed toward VEGFR, PDGFR, c-KIT, and other kinases.
- The ‘858 Patent’s specific compound claims may be challenged or copied in these related patents.
4.3. Patent Filing Trends
- Pre-2010: Increasing filings around kinase inhibitors based on pyrrolopyrimidines.
- Post-2010: Growth in patents covering combinations, formulation improvements, and specific targeting.
5. Patentability and Freedom-to-Operate
- The ‘858 Patent’s claims are broad but may face challenges based on prior art disclosures.
- Claims covering specific substituents or kinase targets may avoid prior art but limit scope.
- Freedom-to-operate assessments must consider the overlapping claims of other kinase inhibitor patents, especially from major pharmaceutical players.
Comparison of the ‘858 Patent Claims to Major Competitors
| Aspect |
‘858 Patent |
Comparable Patent Examples |
Differences / Similarities |
| Chemical Class |
Pyrrolopyrimidines |
Pyrrolopyrimidine derivatives in US Patent 7,585,982 (Pfizer) |
Similar core, different substituents |
| Targeted Kinases |
VEGFR, PDGFR, KIT |
Similar kinases targeted in other patents |
Similar but precise selectivity profiles may differ |
| Claims Breadth |
Broad structural class |
Varies; some more narrow, others broader |
‘858 Patent offers extensive coverage |
Deep Dive: Key Claim Limitations and Potential Weak Spots
| Claim Number |
Limitations / Exclusions |
Potential Infringement Risks |
| Claim 1 |
Must fit the broad structure and substituents |
Narrowed by specific substituents if deviating |
| Claim 37 |
Therapeutic use claims require proof of activity |
Infringement depends on actual use and activity levels |
| Claim 2-36 |
Specific compound variations |
Generic analogs with different substituents may avoid infringement |
Conclusion
The ‘858 Patent provides broad coverage over pyrrolopyrimidine derivatives and their use as kinase inhibitors in cancer therapy. While its scope is extensive, it faces a dense competitive landscape with many patents claiming similar chemical classes and targets. The patent claims’ breadth supports a robust protection strategy but may be challenged or circumvented through specific structural modifications or by demonstrating prior art.
Key Takeaways
- The patent’s compound claims are broad, encompassing a wide chemical space of pyrrolopyrimidine derivatives.
- Method claims cover therapeutic applications, including combination therapies.
- The patent landscape is heavily populated with overlapping patents focusing on kinase inhibitors, especially pyrrolopyrimidines.
- Freedom-to-operate analyses should consider prior art and competitor patents, notably from Pfizer, GSK, and Novartis.
- Maintaining patent strength requires strategic claim drafting, especially emphasizing novel substitutions and specific kinase selectivity profiles.
FAQs
1. Does US Patent 7,662,858 protect all pyrrolopyrimidine compounds?
No. It claims a specific class of pyrrolopyrimidine derivatives characterized by particular structural features; compounds outside these structures are not covered.
2. Can competitors design around this patent?
Potentially, by modifying the core structure or substituents to fall outside the claims' scope, especially if such modifications result in non-infringing compounds.
3. Are method claims for cancer treatment enforceable?
Yes, provided the compounds used meet the parameters of the claims and are effective kinase inhibitors. Patent infringement depends on actual use and activity profiles.
4. How does the patent landscape impact licensing opportunities?
The dense patent environment necessitates careful patent clearance and potential licensing negotiations with patent holders like Pfizer, GSK, or Novartis.
5. What strategic considerations should be made for patentability?
Focusing on novel substituents, specific kinase selectivity, or unique formulations can strengthen patent positions and mitigate infringement risks.
References
[1] US Patent 7,662,858, “Methods for treating diseases with pyrrolopyrimidine compounds,” issued February 2, 2010.
[2] US Patent 7,585,982, Pfizer, “Kinase inhibitors,” issued Sept 2009.
[3] WO 2008/006188, GSK, “Pyrrolopyrimidine derivatives,” published Jan 2008.
[4] US Patent 8,583,149, Novartis, “Selective kinase inhibitors,” issued Nov 2013.
